Medivir's Oncology Asset Purchase Seals TetraLogic's Death
Executive Summary
Medivir, which recently reinvented itself as a solely oncology-based R&D company, is buying two programs for TetraLogic which will subsequently 'terminate all remaining employees'.
You may also be interested in...
Deal Watch: Bristol Leaves Neuropathic Pain Candidate To Lexicon
Verastem steps in where AbbVie exited, agreeing to license Infinity’s duvelisib in hematologic cancer indications. Celldex grows its immuno-oncology pipeline with buyout of private Yale Medical School-spinout Kolltan.
Medivir Abandons Separate Listing, Sells Off Commercial Unit
Medivir has decided a sale of its commercial arm BioPhausia makes better business sense than a separate listing, and is selling the unit to Karo Pharma for just over $100m.
Medivir Plans For A Post-Simeprevir Future
The hepatitis C therapy simeprevir may have been a commercial success for the small Swedish biotech Medivir, but as competition increases and sales decline, the company is planning for what comes next.